Amylyx Pharmaceuticals: Clinical Trial Results Demonstrate Statistically Significant Treatment Benefit in Lou Gehrig’s Disease Patients

Amylyx Pharmaceuticals

With the advancement of biological sciences, and increased information about the pathways of diseases, we are getting more interested in biotech firms that are focused on treating life-threatening diseases as the risk of failure is decreasing.  The successful outcome of trials would tremendously boost the values of these firms as we have witnessed in many small biotech firms that became large firms and others that were taken over at billions of dollars.

Amylyx Pharmaceuticals, although a privately trading firm, is attracting our attention and motivating us to follow up on its accomplishments. Amylyx was founded in 2013 to improve the lives of patients with neurodegenerative diseases.  The firm’s lead therapeutic, AMX0035, is designed to target pathways originating in the mitochondria and endoplasmic reticulum which lead to neuronal death and degradation. AMX0035 is currently in clinical trials for both Alzheimer’s disease and Amyotrophic lateral sclerosis (ALS).

What is AMX0035? 

Leave a Reply